Form 4: Corcept Therapeutics Officer Exercises Options, Sells Shares

A Corcept Therapeutics officer exercised stock options and subsequently sold a matching number of shares, while also acquiring new shares and restricted stock awards.

Summary

• Sean Maduck, President of Corcept Endocrinology, exercised options to acquire 20,000 shares of common stock at $5.05 per share on September 2, 2025.
• On the same day, Maduck sold a total of 20,000 shares (15,070 shares at a weighted average price of $70.3787 and 4,930 shares at a weighted average price of $70.8359). These sales were conducted under a Rule 10b5-1 plan adopted on September 5, 2024.
• Maduck also purchased 228 shares at $71.38 and received 228 shares as unvested restricted stock awards under a purchase plan on September 2, 2025.
• On September 3, 2025, 233 shares were withheld by the Issuer to satisfy tax obligations related to the vesting of restricted stock units, valued at $71.38 per share.
• Following these transactions, Maduck directly holds 7,904 shares.
• Indirect holdings include 59,717 shares via Sean and Molly Maduck Living Trust, 40,000 shares via SNM 2025 Grantor Retained Annuity Trust, and 10,000 shares via Duckhill Capital, LLC (beneficial ownership disclaimed except for pecuniary interest).

Sentiment

Score: 5

Explanation: The officer exercised a significant number of options and immediately sold an equivalent amount of shares, which is a common profit-taking strategy. While new shares were acquired through a purchase plan and restricted stock awards, the net effect on direct beneficial ownership from these transactions is a reduction, suggesting a neutral to slightly negative sentiment regarding the officer's immediate personal stake, despite the pre-planned nature of the sales.

Positives

• Exercise of stock options at a low strike price ($5.05) indicates a significant in-the-money position.
• Acquisition of 228 shares through a purchase plan and an additional 228 unvested restricted stock awards demonstrates continued investment and alignment with company performance.
• The existence of unvested restricted stock awards (265, 266, 888 shares from previous grants, plus the new 228 shares) indicates ongoing long-term incentives for the reporting person.

Negatives

• The sale of 20,000 shares, immediately following the exercise of options, represents a significant reduction in direct holdings, potentially signaling a desire to monetize gains.
• The sales were executed at prices ranging from $69.72 to $71.09, which are substantially higher than the exercise price, indicating a profit-taking event.

Related Party Transactions

• Shares held by Sean and Molly Maduck Living Trust (59,717 shares), where the Reporting Person is a co-trustee.
• Shares held by SNM 2025 Grantor Retained Annuity Trust (40,000 shares), where the Reporting Person is the trustee.
• Shares held by Duckhill Capital, LLC (10,000 shares), where the Reporting Person is President and disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: Insider sales, even pre-planned, can sometimes be perceived negatively, though the context of option exercise mitigates this. The officer still retains significant indirect holdings.

Next Steps

• Vesting of 265 restricted stock awards on December 2, 2025.
• Vesting of 266 restricted stock awards on March 3, 2026.
• Vesting of 888 restricted stock awards on June 2, 2026.
• Vesting of 228 restricted stock awards (from Purchase Plan) on September 2, 2026, contingent on retaining Purchase Plan Shares.

Key Dates

Recommendation

The filing details a pre-planned insider transaction where an officer exercised options and immediately sold an equivalent number of shares. This is a common profit-taking strategy and does not necessarily indicate a lack of confidence in the company's future. The officer still retains substantial indirect holdings and has received new restricted stock awards, suggesting continued alignment. Without additional information on company performance or strategic shifts, this transaction alone warrants a 'hold' recommendation, as it's a scheduled event rather than a reactive one.

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, Stock Options, Share Sale, Restricted Stock, Sean Maduck, Officer Transaction, 10b5-1 Plan